Pain Management Best Practices from Multispecialty Organizations During the COVID-19 Pandemic and Public Health Crises

Steven P. Cohen, MD,* Zafeer B. Baber, MD,‡ Asokumar Buvanendran, MD,§ Brian C. McLean, MD,¶ Yian Chen, MD, W. Michael Hooten, MD, Scott R. Laker, MD,** Ajay D. Wasan, MD, MSc,†† David J. Kennedy, MD,‡‡ Friedhelm Sandbrink, MD,§§ Scott A. King, MD,¶¶ Ian M. Fowler, MD,*** Milan P. Stojanovic, MD,††† Salim M. Hayek, MD, PhD,‡‡‡ and Christopher R. Phillips, MD§§§

*Anesthesiology, Neurology and Physical Medicine and Rehabilitation, Pain Medicine, Johns Hopkins School of Medicine, Maryland; ‡Anesthesiology and Physical Medicine and Rehabilitation, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland; †Division of Anesthesiology and Interventional Pain Management, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts; §Anesthesiology and Orthopedic Surgery, Rush University College of Medicine, Chicago, Illinois; ¶US Army Pain Management Consultant, Pain Management, Department of Anesthesiology, Tripler Army Medical Center, Honolulu, Hawaii; ‡Department of Anesthesiology, Johns Hopkins School of Medicine, Baltimore, Maryland; **Anesthesiology and Psychiatry, Mayo School of Medicine, Rochester, Minnesota; ***Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Denver, Colorado; ††Anesthesiology and Psychiatry, Pain Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; ‡‡Department of Physical Medicine & Rehabilitation, Vanderbilt University School of Medicine, Nashville, Tennessee; †††Anesthesiology, Critical Care and Pain Medicine Service, Interventional Pain Medicine, Edith Nourse Rogers Memorial Veterans Hospital, VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts; ‡‡‡Anesthesiology, University Hospitals, Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio; §§§Department of Surgery, Anesthesiology Service, Naval Medical Center- San Diego, California, USA

Correspondence to: Steven P. Cohen, MD, Department of Anesthesiology and Critical Care Medicine, 550 N. Broadway, Suite 301, Baltimore, MD 21205, USA. Tel: 410-955-7246; Fax: 410-502-6730; E-mail: scohen40@jhmi.edu.

Funding sources: SPC is funded by MIRROR, Uniformed Services University of the Health Sciences, US Department of Defense, grant #HU00011920011.

Conflicts of interest: The authors have no conflicts of interest to declare.

Disclaimer: The views expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Departments of the Army, Navy, or Air Force, or the US Government. For the active duty service members, this work was prepared as part of official duties. Title 17, USC $105 provides that copyright protection under this title is not available for any work of the US Government. Title 17, USC $101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties.

Abstract

Background. It is nearly impossible to overestimate the burden of chronic pain, which is associated with enormous personal and socioeconomic costs. Chronic pain is the leading cause of disability in the world, is associated with multiple psychiatric comorbidities, and has been causally linked to the opioid crisis. Access to pain treatment has been called a fundamental human right by numerous organizations. The current COVID-19 pandemic has strained medical resources, creating a dilemma for physicians charged with the responsibility to limit spread of the contagion and to treat the patients they are entrusted to care for. Methods. To address these issues, an expert panel was convened that included pain management experts from the military, Veterans Health Administration, and academia. Endorsement from stakeholder societies was sought upon completion of the document within a one-week period. Results. In these guidelines, we provide a framework for pain practitioners and institutions to balance the often-conflicting goals of risk mitigation for health care providers, risk mitigation for patients, conservation of resources, and access to pain management services. Specific issues discussed include general and intervention-specific risk...
mitigation, patient flow issues and staffing plans, telemedicine options, triaging recommendations, strategies to reduce psychological sequelae in health care providers, and resource utilization. Conclusions. The COVID-19 public health crisis has strained health care systems, creating a conundrum for patients, pain medicine practitioners, hospital leaders, and regulatory officials. Although this document provides a framework for pain management services, systems-wide and individual decisions must take into account clinical considerations, regional health conditions, government and hospital directives, resource availability, and the welfare of health care providers.

Key Words: COVID-19; Pandemic; SARS-CoV-2; Pain Management; Public Health Crisis

Introduction

Epidemics are a category of disease that seem to hold up the mirror to human beings as to who we really are. They show the moral relationships that we have toward each other as people.

Frank Snowden, Medical Historian

It is difficult to estimate the personal and socioeconomic burdens imposed by chronic pain. Pain is the number one reason people seek medical care, and chronic pain conditions comprise three of the top four leading causes of years lost to disability in the United States (back pain, general musculoskeletal disorders, and neck pain) [1,2]. Worldwide, low back pain by itself ranks in the top 10 causes of years lost to disability, being higher in industrialized countries [3]. According to the 2008 Medical Expenditure Panel Survey (MEPS), the estimated annual cost of chronic pain in the United States was between $560 and $635 billion in 2010 dollars, exceeding the cost of heart disease, cancer, and diabetes [4]. Systematic reviews have found a correlation between chronic pain, suicide, and decreased life expectancy [5,6].

In a highly cited study involving 8,781 people who completed the 2012 National Health Interview Survey, Nahin [7] estimated that 55.7% of US adults have experienced pain in the past three months, with 32% experiencing pain every or almost every day and 11.2% reporting severe, debilitating pain. Similar prevalence rates have been reported elsewhere, with a systematic review performed on studies conducted in the UK finding a pooled prevalence rate for chronic pain of 43.5%, with up to 14% suffering from moderate to severe disabling pain [8].

Given the crucial role chronic pain plays in an individual’s physical and psychosocial well-being, access to pain management services has been described as a fundamental human right, similar to the right to access basic medical care, housing, and free speech [9,10]. Pain management physicians have a moral and ethical responsibility to address pain, which can have profound, widespread consequences if left untreated. The undertreatment of pain has been causally linked to the opioid crisis, and chronic pain levels have been associated with increased mortality rates in cancer patients, structural and functional alterations in the brain, poverty, and decreased life expectancy when controlling for other factors [5,11–14]. Demographic factors associated with chronic pain and its undertreatment include lower socioeconomic status, being an African American or other underrepresented minority, and serving on active military duty [15–17]. Yet, physicians also have a professional responsibility to care for their own health and the health of nonphysician health care providers involved in the care of pain and other patients, including preventing the spread of infectious disease. Balancing patient rights, the societal benefits inherent in the treatment of pain, the public health of our community, and the welfare of health care providers is critically important during times of crisis, including epidemics. The objectives of this article are to educate providers, health care leaders, and regulatory bodies on the issues related to pain care during epidemics and to provide a framework for guidelines moving forward.

Need for Guidance

Pain is inherently subjective, and there is enormous variation in how patients report their pain, how patients react to pain, and how it is treated, even between physicians from the same subspecialty. Traditionally, pain management has not been considered a high priority in austere environments or times of crisis, such that the US military deploys board-certified pain management physicians only in their primary specialty [18]. Patients with the same pathology can respond dramatically differently to treatment and react in myriad ways to having anticipated treatment withheld, including becoming socially withdrawn, functionally disabled, and suicidal. Large variations in practices within regions can have long-standing consequences, such that practices that strictly interpret local recommendations to limit nonessential care to prevent disease spread can lose patients to less scrupulous practices that ignore regional ordinances intended to safeguard the community. For these reasons, there is a strong need for national guidance on pain management practices during epidemics.

Methods

Amidst repeated inquiries from pain medicine physicians military specialty leaders, pain management and other interventional societies, and the American Society of
Anesthesiologists (ASA) asking for guidance on pain management practices during the COVID-19 pandemic, a conference call was held on March 19, 2020, to determine the need for pain management guidelines. Pain management leaders from the Veterans Health Administration (National Program Director for Pain Management), the US military (Pain Management Specialty Leaders for the Army, Navy, and Air Force), medical societies, and academia were invited. An outline was prepared based on the conference call, with a suspense date of 10 days for submission of sections. Given the rapidly evolving situation and the real-time dispensation of medical information via nontraditional venues, authors were given wide latitude in preparing their sections, with no restrictions on sources, search engines, types of articles, or language. A second call was held on March 26, 2020, at which time it was decided to seek endorsement from stakeholder societies, with a one-week suspense date. The document was sent to the Boards of Directors of the American Society of Regional Anesthesia and Pain Medicine (ASRA), American Academy of Pain Medicine (AAPM), Spine Intervention Society (SIS), North American Neuromodulation Society (NANS), and World Institute of Pain (WIP), all of which endorsed the document, with minor revisions. The final document was also supported by the ASA and the American Academy of Physical Medicine and Rehabilitation (AAPMR) and approved for dissemination by the Dept. of Defense. The article was submitted for publication to *Pain Medicine* on March 29, 2020, and accepted on April 1, 2020.

**SARS-CoV-2/COVID-19 Background**

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is related to the coronavirus, which caused SARS in 2003. The virus is transmitted either through airborne droplets (e.g., coughing, sneezing, or even respiration) or direct contact (e.g., via contact with a surface, including medical equipment such as a pulse oximeter or nasal cannula containing the virus), with a mean incubation period (range) of between four and seven days (2 days–2 weeks) [19,20]. The latest data as of April 2020 indicate that the virus is shed from the nasopharynx for a median (range) of 20 (8–37) days after illness onset [21]. Although individuals are most infectious when they are at the peak of their symptoms, the virus can still be transmitted person-to-person in individuals who are asymptomatic or have subclinical symptoms, which is most likely to occur in individuals living together or in close physical contact; this scenario accounts for a majority of cases. Based on the latest data, there appears to be only a small chance that brief contact with an asymptomatic carrier of the virus when both parties take proper precautions, such as that which might occur during a focused pain medicine encounter, confers any appreciable risk of becoming infected.

COVID-19 generally presents as a mild respiratory tract infection characterized by a dry cough, fatigue, and a low-grade fever; however, it may rapidly progress to respiratory distress requiring intensive care, with a case fatality rate of 1% to greater than 5% depending on region [22]. As of May 31, there were >1.8 million confirmed cases and over 105,000 deaths in the US, for a case fatality rate exceeding 5% [23]. The intensive care unit (ICU) admission and case fatality rates are significantly higher with increasing age, and while ICU admissions and deaths in children have been recorded, they are rare in the United States. ICU admission and case fatality rates steadily rise from 4.7–11.2% and 1.4–2.6%, respectively, in the 55–64-years age group, to 6.3–29% and 10.4–27.3% in people >85 years of age [24]. However, given that not everyone who needs to be tested gets tested and that many individuals develop only minor or no symptoms, these rates are almost certainly lower. In addition to age, other risk factors for greater disease burden and mortality include smoking and preexisting medical conditions such as asthma, chronic obstructive pulmonary disease, congestive heart failure, diabetes, and AIDS [25–27].

**General Risk Mitigation**

Although pain management providers care for a generally healthy subset of the medical population, infection control precautions form a backbone of intervention-based (e.g., injections) and some alternative medicine (e.g., acupuncture, hands-on therapies such as massage and manual therapy) practices. Yet, these precautions are even more important during a pandemic, where the potential exists for viral shedding from asymptomatic patients and disease transmission. The Centers for Disease Control and Prevention (CDC) has provided infection control recommendations for preventing the transmission of infectious agents in health care settings, which can be accessed via https://www.cdc.gov/infection-control/guidelines/isolation/. These recommendations and others that are most applicable to interventional pain physicians include:

- Screen patients, and consider checking temperatures on all patients entering the clinic.
- Place signs at triage points to instruct patients on appropriate hand hygiene, respiratory hygiene, and cough etiquette. Provide adequate supplies in visible and accessible areas.
- Triage patients with fever and or respiratory symptoms, and ensure that triage personnel have a supply of face masks to apply to symptomatic and asymptomatic patients as resource availability and ground conditions indicate, as viral shedding may occur during respiration.
- Limit unnecessary patient escorts.
- Create an area for spatially separating patients, ideally at least six feet apart in waiting rooms and at check-in or booking locations/queues.
Patients should be seen in a clean room, with no prior exposure to COVID-19 patients. If patients with COVID-19 or those suspected of having COVID-19 have been in the room, the room needs to be adequately disinfected.

Hand hygiene should be performed with a 60–95% alcohol-based hand rub for 15 seconds or with soap and water for at least 20 seconds before and between all patient care episodes.

Strongly consider the use of surgical, procedural, or cloth face masks, or ideally face shields if available, during any patient interaction. This may prevent viral spread from an asymptomatic health care worker to patients, ancillary staff, or other health care workers.

In areas with community spread, providers can change into scrubs before seeing patients and out of scrubs before leaving the hospital.

Avoid touching one’s face during exposures; wearing a regular face mask if available during in-person visits may serve as a reminder and physical barrier against respiratory shedding.

Wear gloves during patient care, and remove and discard gloves when leaving the care area; immediately perform hand hygiene.

During procedures, sterile attire should be discarded after patient treatment, provided resources are adequate (e.g., do not routinely reuse regular masks on different patients if resources permit).

During evaluations and routine nonaerosolizing procedures, surgical masks are considered adequate and N95 masks are not needed. For high-risk patients, providers may choose to protect themselves with particulate-filtering respirators. For N95 masks, limited reuse is permissible during times of shortage.

Clean and disinfect all surfaces in the patient care environment, to include tables, beds, chairs, door handles, and equipment between each patient encounter.

In addition to taking actions to protect the health and safety of patients, pain management staff should also take action to protect and preserve their health, resiliency, and endurance to be able to continue to provide safe and effective care to their patients. Along with the general infection control recommendations above, during a pandemic providers should take additional actions, to include:

- Avoid unnecessary contact with others.
- Avoid unnecessary travel.
- Ensure access to adequate levels of necessary sustenance and medications.
- Ensure adequate sleep and hydration.
- Optimize one’s health and immune system through behavioral changes such as quitting smoking and tobacco abuse, limiting alcohol use, and improvements in diet and exercise.
- Plan for activities and alternative methods of socialization and communication during times of isolation.
- Proactively manage stress and provider burnout by monitoring your staff, providing resources as needed, and practicing proper work-rest cycles.

### Specific Risk Mitigation

For emergent procedures or consultations that need to be performed in high-risk patients (i.e., those with COVID-19 symptoms, those with close contact with COVID-19 patients or those suspected of having the disease, individuals with recent travel to high-risk areas) or those known to be infectious, N95 masks should be used. For individuals who have not been N95 fit-tested, have facial hair, or fail N95 fit-testing, powered air-purifying respirators (PAPRs) should be used if possible [28]. Surgical face masks protect against COVID-19 droplet transmission but do not reliably protect against aerosolized small particles.

N95 masks are defined by the National Institute for Occupational Safety and Health’s (NIOSH’s) respirator approval criteria as a filter class that removes at least 95% of the “most-penetrating” sized airborne particles during a NIOSH standardized test procedure [29]. Although N95 masks, like other transmission barriers, should ideally be disposed of and changed between patients, during pandemics and times of equipment shortage when contact transmission is not a concern (e.g., fomites), guidance from federal organizations recommends that a respirator classified as disposable can be reused by the same worker as long as it remains functional, which is termed “limited reuse” [30–32]. If masks are reused, the greatest risk stems from survival of the pathogen on the respiratory surface, which can be transmitted by hand contact [33]. Steps to reduce this risk include wearing cleanable face shields over the N95 mask or masking patients to reduce the chance of contamination, limiting the number of uses (five uses in the absence of specific manufacturer recommendations), visual inspection for body fluids or damage, repeat fit-testing to ensure continued effectiveness, washing hands and using gloves before doffing and donning equipment, and proper storage between uses [34].

### Procedures

Although procedures by necessity require hands-on exposure and are often considered to pose high infection risk, risk is governed by multiple factors, including exposure time, body regions exposed, previsit risk mitigation, venue, etc., and for some of these the risk be lower for simple procedures compared with new patient evaluations. Unlike new patient encounters, procedures involve patients who are already known to physicians and do not typically require a complete physical exam. For the most common procedures performed, patients are positioned face down, and the contact area is limited and steriley prepped. Similar to open surgical procedures, providers may request that patients shower before receiving injections in high-risk situations. If available, masks should be provided to patients to reduce the risk of droplet spread, especially in areas with community spread. When performing procedures with the potential for aerosolization such as intranasal sphenopalatine ganglion blocks and intra-oral injections, N95 masks should be used as recommended by the CDC and ASA [35]. Procedures should be performed with the minimal number of personnel,
ideally by a physician with extensive experience, to minimize risk exposure. In academic or group practices that have significantly diminished patient loads, whereby procedure time is limited to a few hours per day or a couple of sessions or days per week, consideration should be given to designating one person to perform all procedures during the allotted time slot to minimize practitioner exposure. Barring exigent circumstances, deep sedation that may require airway support or high flow oxygen should be avoided.

High-Risk Patients
In-person visits and procedures should be limited to urgent or emergent cases, and the meeting or procedure should ideally be conducted in a room designated for such purposes (if none is available, steps must be taken to adequately disinfect the room afterwards). In high-risk patients or in areas with a high density of infections (i.e., where there is community spread), institutions may require patients who need a procedure, or who are being seen in person, to undergo a polymerase chain reaction (PCR) test, ideally within 48 hours of the visit. Unlike serology testing which detects antibodies indicative of exposure, PCR is capable of detecting viral genetic material, which should be positive with active shedding (i.e., the patient is infectious). During visits, the use of common areas should be avoided, such that the patient is transported directly to the encounter area. Physicians who treat high-risk patients should be adequately protected with the use of surgical masks and face shields. The use of N95 masks should be considered on a case-to-case basis depending upon local availability and necessity (e.g., risk of coughing or sneezing by the patient). After the encounter, the patient should be monitored in the room until they can be transferred to an appropriate isolation area or discharged home to quarantine. It has been demonstrated that risk of transmission is highest during removal of protective gear, so appropriate precautions should be taken during this time period. It is critical that one’s hands are cleansed thoroughly after the encounter and that providers avoid touching their face or other surfaces before this is done. Pre-encounter briefings, simulation sessions if needed, and the presence of an observer during the removal and discarding of protective gear are highly recommended.

Staffing Plans
In a public health crisis, it is important for institutions to develop staffing plans that prevent or minimize “unnecessary” exposure of hospital staff to patients and to themselves. In scenarios characterized by widespread community transmission, it is essential to minimize interactions between clinic staff and the public; achievement of this goal can be optimized by following pathways such as the CDC Hospital Pandemic Influenza Planning Checklist [36]. Steps that are recommended include identifying staff deemed nonessential to the direct care of the patient during a pandemic. This may include certain medical assistants, nurse’s aides, and scribes. Second, time must be taken to identify specific roles that can be performed remotely. This may include billers, translational services, and secretarial staff. Finally, physicians may be able to do telehealth appointments from home if they have an electronic medical record infrastructure that supports it.

Once key medical personnel are identified, steps can be taken to ensure that only those essential to the physician–patient interaction are allowed to enter the hospital and patient care areas. This may require special badges for essential staff, confirmation of clinic appointments when patients enter the hospital, and placing limits or moratoriums on patient guests. If the patient requires a caregiver at their side, they may need to limit their guests to one adult and no children. For minimally invasive procedures that typically require escorts such as lumbar epidural steroid injections performed without local anesthetic, requirements may be waived on an “as-needed” basis. Alternatively, escorts may be asked to wait in their vehicle instead of physically accompanying the patient to the procedure area. Finally, necessary in-person clinic appointments should be spaced out appropriately to prevent clinic overcrowding, and patients should not be allowed in the facility outside an appropriate time window for their appointment. Enforcement of these rules may require additional security personnel.

Some experts recommend PCR testing for healthcare providers in areas with very high rates of infection, though this strategy is limited by the need to continue testing those who screen negative, the false-positive and negative rates, and the invasiveness of the test. Perhaps a more palatable strategy in high-risk areas is for healthcare providers to self-screen themselves, and to check temperatures on those entering the office.

It is important to point out that federal, state, and local regulations concerning safety, including those of the hospital, supersede those of individual clinics. Such directives may come from the Department of Health and Human Services, the Office of the US Surgeon General, local state departments of health, or the CDC. The CDC also provides guidance for state and local health care systems regarding infection control and patient treatment [37], thus standardizing a national response across health care systems. In emergencies, pain clinic resources such as procedural gear and personal protective equipment (PPE) may be diverted toward addressing the pandemic. Procedural areas including those usually reserved for performing procedures or recovering patients may be utilized to address overflow patients in respiratory distress, and clinical nursing staff may be transitioned to caring
for those patients. Anesthesiologists specializing in pain medicine may be diverted to managing ventilated patients.

**Telemedicine Options**

**Billing and Logistics**

The US Department of Health and Human Services (HHS), responsible for enforcing regulations under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), released guidance that during the COVID-19 national emergency and nationwide public health emergency, providers subject to the HIPAA Rules may utilize technology for communicating with patients that does not meet all requirements. The Office of Civil Rights (OCR) within HHS has exercised its “enforcement discretion to not impose penalties for non-compliance with the HIPAA Rules in connection with the good faith provision of telehealth.” Popular applications that are not typically permitted, including Apple FaceTime, Facebook Messenger video chat, Skype, etc., may be used without risk of penalty for noncompliance during this emergency; however, public-facing applications in which the video encounter cannot be kept private (Facebook Live, Twitch, TikTok, etc.) should not be used [38].

The recently passed Coronavirus Preparedness and Response Supplemental Appropriations Act and 1135 waiver authority have permitted the Centers for Medicare and Medicaid Services (CMS) to expand telehealth by authorizing Medicare payments at the same rate as in-person visits for “office, hospital, and other visits furnished via telehealth across the country including in patients’ places of residence starting March 6, 2020.” Currently, CMS has added over 80 codes to the list of services that can be provided via telehealth. Billing should be conducted using the appropriate telehealth modifier (e.g., place of service code 02 for Medicare or the modifiers “95” and “GT” for some private insurance companies). It is important to recognize that relaxed billing processes apply only to telehealth video encounters and not uniformly to audio encounters only (such as phone calls). Previous CMS guidelines requiring the patient to travel to a certified telehealth center (place of service) are no longer broadly applicable. Physicians and other healthcare practitioners are now able to provide telehealth services from their home, and bill from their current enrolled location. Medicare telehealth visits previously required interactive audio and video telecommunications systems that permit real-time communication, with billing modifiers used in circumstances where interactive video is not feasible or practical, though on April 30, 2020, CMS waived the video requirement retroactive to March 1, 2020. As of March 6, 2020 and extending through the duration of this public health crisis, appropriately performed telehealth visits can be reimbursed by Medicare at the same rate as in-person visits, though the level of encounter may need to be downgraded sans physical exam, or because the practitioner spends less time with the patient using time-based billing. It is important to recognize that private insurers are not required to adhere to CMS policies, and their requirements may be different.

The HHS has asserted that audits ensuring a prior relationship between patient and particular practitioner will not be conducted during this public health emergency, thus allowing new patient intakes to be completed through an audio/video encounter [39]. Licensing for telemedicine is at the discretion of each state, and all states require providers to be licensed in the state in which the patient receives the care. There are now 12 states that offer special telemedicine licenses that allow cross-state line visits [40]. In the wake of the public health emergency declared by the Secretary of Health and Human Services, the US Drug Enforcement Agency now permits Drug Enforcement Agency–registered physicians to prescribe opioids via telehealth visits, provided they are issued for a legitimate medical purpose by a practitioner acting in the usual course of his/her professional practice; the telemedicine communication is conducted using an audiovisual, real-time, two-way interactive communication system; and the practitioner is acting in accordance with applicable federal and state law. On March 25th, the DEA waived the requirement that a DEA registrant must be registered in the state where the practitioner dispenses controlled substances, and on March 27th, they allowed photographed and scanned prescriptions for emergencies. Telephone-only visits are acceptable for opioid refills and for initiating buprenorphine therapy.

**Monitoring Patients for Opioid Withdrawal**

In patients on opioids who may have run out of medications because of logistical obstacles or overuse, assessment of withdrawal signs can be challenging during remote visits. Symptoms such as diarrhea, rhinorrhea, abdominal pain, and chills can be garnered from patient interviews but may be difficult to corroborate. However, some physical signs indicative of opioid withdrawal, particularly if prominent, can be observed remotely, such as agitation, diaphoresis, piloerection, and possibly even pupillary size. Monitoring patients for an elevated heart or pulse rate, which is a classic sign of opioid withdrawal, can sometimes be done by reliable patients or their caregivers. Although not usually fatal, patients at risk for opioid withdrawal should be scheduled for an in-person visit if possible. Nonopioid strategies to prevent physical withdrawal can include clonidine and lofexidine.

**Telehealth Therapy**

Mobile health technology has generated intense interest in the pain medicine community. Given its focus on self-
care and Web-based or other forms of remote communication, psychological treatments such as cognitive behavioral therapy, mindfulness therapy, and Acceptance and Commitment Therapy, would seem to be prime candidates for remote administration. In a review on mobile health technology for chronic pain, Sundararaman et al. found that while the results were promising and widespread adoption was likely to be the norm in years to come, to date rigorous trials have yet to be conducted [41]. The argument in favor of trialing mobile health psychological treatments may be even more compelling during these times of pandemic-related personal and social stress.

The use of mobile technology to facilitate physical modalities such as yoga, tai chi, and home exercise programs has also grown exponentially in the past decade. Yet, similar to psychology-based therapies, reviews have generally found that while preliminary findings have been auspicious, the studies tended to be small and characterized by methodological flaws and bias [42]. In one systematic review that examined 648 studies evaluating the efficacy of electronic health–supported home exercise interventions, the authors found only seven randomized trials that met inclusion criteria. They concluded that while there was evidence to support improvement in pain scores, function, and health-related quality of life, the degree of benefit was small and of questionable clinical relevance [43]. Nevertheless, given their very low risks, the absence of suitable alternatives, and the non-pain-related benefits that may be afforded by exercise and psychological therapies in times of crisis, it is recommended that telehealth modalities be utilized whenever possible if indicated. Although there is often scant and conflicting evidence even for the most commonly utilized in-person pain interventions, the absence of evidence (for an effect) is not the same as evidence of absence.

Clinic Flow

During public health emergencies including pandemics, patients must still be afforded access to pain specialist care. Patients presenting for in-person care should be screened for symptoms of acute respiratory illness (e.g., fever, cough, difficulty breathing) before entering the facility. Patients with respiratory symptoms who require urgent care should have a separate waiting space and evaluation/treatment area (or be brought directly into the evaluation/treatment area) and wear a mask to contain any droplets. All patients should have access to alcohol-based hand rub (ABHR) and/or soap at a sink. Chairs in the waiting room should be placed six feet apart, and reading materials and other communal objects should be removed or cleaned regularly [44,45].

All members of the health care team should perform hand hygiene before and after all patient care episodes or contact with any potentially infectious material. Hand hygiene should be performed with an ABHR that is 60–95% alcohol or by washing hands with soap and water for at least 20 seconds. N95 respirators (level 3 face mask if unavailable) or PAPRs should be used by staff who are present during an aerosol-generating procedure. Eye protection, gloves, and gowns are also recommended for any interaction, but gowns can be prioritized for aerosol-generating procedures, care activities where splashes and sprays are anticipated, and high-contact patient care activities (e.g., patient hygiene) [44,45].

Triage

*It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has.*

*William Osler*

The term “triage” derives from the French word “trier,” which means “classifying” or “categorizing.” Although the concept can apply to any scarce resource, it is most commonly used to describe the prioritization of patients based on their need for treatment [46]. Triage allows first responders, who may lack resources, to prioritize care. In catastrophic situations, there is a switch in the care paradigm from doing what is best for the individual patient to doing what is best for the largest number of people [47,48].

Although triage is sometimes considered by non-emergency room providers to be tedious administrative work, it is well known that in mass casualty situations, better outcomes can be obtained when more experienced personnel triage patients. In emergency departments, the Joint Commission actually requires recertification for triage personnel every three years. In situations where resources are scarce (critical shortages in personnel or personal protective equipment), treatment decisions may be decided by small subcommittees, as has been described in disaster situations [49].

On April 7, 2020, CMS developed a framework to prioritize medical services during COVID which consists of 3 tiers. Tier one involves low acuity treatments or services (e.g. routine procedure follow-ups, check-ups), tier two comprises intermediate acuity treatments or services (e.g. development of new symptoms in an established patient, ), and tier 3 consists of high acuity treatments and services such that lack of in-person treatment would be likely to result in harm (e.g. evaluation of new symptoms in a new patient, an injection in someone whose condition is likely to deteriorate without it [50].

Practically, triaging for pain is more challenging than for trauma, where more objective criteria (e.g., urgent threat of loss of life, limb, or eyesight) can be used. There is generally a poor correlation between imaging findings and pain and disability, and there is a bi-directional relationship between chronic pain and psychiatric comorbidities such as depression [51,52]. Given the absence of specific biomarkers for pain, its subjective nature, and.
the high variability in response to acute and chronic pain, triaging pain medicine patients can be extremely challenging.

The American College of Surgeons recommends that not only medical factors but also logistical circumstances be considered when making treatment decisions [53]. For pain management, factors that should be taken into consideration when deciding whether to see a patient in person, change the appointment to telemedicine, postpone the visit, or perform a procedure include (Tables 1 and 2, Figure 1):

- acuity;
- comorbid psychiatric (e.g., severe pain-related depression) and social (e.g., single mother of young children with limited resources) considerations;
- pain level and accompanying functional impairment;
- likelihood of the visit/procedure providing meaningful benefit;

**Table 1. Suggestions for procedure triage**

| Procedure Order | Procedure Type | Decision |
|-----------------|----------------|----------|
| Emergent        | • Complication in any currently implanted patient; examples include infection or wound dehiscence | Proceed, do not postpone |
|                 | • Stage 2 of a DRG or SCS implant with external leads | |
|                 | • Epidural blood patch for incapacitating postdural puncture headache or intractable intracranial hypotension† | |
|                 | • Migration of SCS, DRG leads, leading to neurological deficits or severe pain | |
|                 | • Intrathecal pump refill or malfunction | |
|                 | • Epidural or paraver tbral catheter for rib fractures | |
|                 | • Neurolytic procedures for refractory cancer-associated pain | |
|                 | • Epidural steroid injections for acute disc herniation or acute pain exacerbation associated with serious neurological deficits | |
|                 | • Vertebroplasty of kyphoplasty for refractory pain from acute vertebral compression fracture§ | |
|                 | • Replacement of neurostimulation devices in which there is a high likelihood that abrupt cessation of therapy will lead to decompensation | |
|                 | • Sympathetic blocks for early complex regional pain syndrome after conservative treatment failure | |
|                 | • Treatments for acute or acute exacerbations of refractory spinal pain where there is a high likelihood of physical or psychological disability (radiofrequency ablation in a person with disabling recurrence after previous relief, sacroiliac joint injection for acute, disabling pain) | |
|                 | • Debilitating nerve entrapment syndromes with neurological deficits | |
|                 | • Acute headaches likely to respond to blocks (e.g., occipital neuralgia, trigeminal neuralgia)³ | |
| Urgent (may consider on case-to-case basis)⁺ | | Consider and discuss risks and benefits with patient and facility. May proceed after screening if resources support. |
|                 | • Neurmodulation (conventional spinal cord stimulation or peripheral nerve stimulation) | |
|                 | • Ketamine and other intravenous infusions k | |
|                 | • Epidural steroid injections for chronic pain | Postpone or cancel |
|                 | • Selective nerve root blocks | |
|                 | • Diagnostic medial branch blocks, most intra-articular facet blocks, and repeat preemptive radiofrequency denervation for chronic pain | |
|                 | • Trigger point injections | |
|                 | • Diagnostic discography | |
|                 | • Peripheral intra-articular joint injections (hip, knee, etc.) | |
| Elective        | • Neuromodulation (conventional spinal cord stimulation or peripheral nerve stimulation) | |
|                 | • Ketamine and other intravenous infusions k | |
|                 | • Epidural steroid injections for chronic pain | |
|                 | • Selective nerve root blocks | |
|                 | • Diagnostic medial branch blocks, most intra-articular facet blocks, and repeat preemptive radiofrequency denervation for chronic pain | |
|                 | • Trigger point injections | |
|                 | • Diagnostic discography | |
|                 | • Peripheral intra-articular joint injections (hip, knee, etc.) | |
|                 | • Neuromodulation (conventional spinal cord stimulation or peripheral nerve stimulation) | |
|                 | • Ketamine and other intravenous infusions k | |

DRG = dorsal root ganglia; SCS = spinal cord stimulator.

*Anesthesia or deep sedation that may require airway support should be avoided if at all possible.

†Postdural puncture headaches are generally time-limited, and first-line treatments can include conservative care. Reserved only for refractory, debilitating cases.

⁺Psychosocial factors, work status, acuity, likelihood and anticipated magnitude of benefit, treatment alternatives, infectious and other risks associated with the procedure, and chances the patient will seek emergency services or begin opioid therapy may all be considered. Urgent procedures should ideally be done in < 4 weeks.

§Vertebral compression fractures may be associated with significant morbidity in the elderly. Mixed evidence for effectiveness. Discuss risks and benefits with patients, participating health care personnel, and facility leadership. May proceed if resources support.

³Trigeminal neuralgia affects mostly elderly patients, who are at increased risk for infection. There is weak evidence of long-term effectiveness for trigeminal nerve blocks. Urgency depends on context. Intranasal sphenopalatine ganglion blocks may cause viral aerosolization and should be used with extreme caution as a last resort in high-risk patients.

kMay be considered urgent in individuals for whom ketamine has previously been successfully used to treat refractory pain and depression (i.e., ongoing treatment).
Managing Opioids

Opioids are the most efficacious treatment for acute and possibly chronic pain, having demonstrated efficacy for both neuropathic and non-neuropathic pain [54,55]. Although critics cite a lack of high-quality evidence supporting benefit for longer than three months, systematic reviews have demonstrated long-standing improvement.
in quality of life. The absence of long-term efficacy data stems from regulatory requirements and ethical considerations about the enduring use of placebo, and the same criticism can be leveled against nonopioid treatments [13,56].

Psychological stress has been causally linked to exacerbations of chronic pain, but has also been shown to amplify opioid craving in individuals with a history of opioid misuse and to increase the risk for opioid abuse and relapse [57–59]. In addition to pain, patients frequently use medically prescribed opioids consciously and unconsciously to alleviate non-pain-related psychological symptoms that may emerge from or be magnified during public health crises, including depression, sleep, and anxiety. Whereas there is some evidence in the form of small controlled and uncontrolled trials to support opioids in the short term for each of these conditions [60–62], their long-term use in this context is likely to exacerbate these symptoms [63–65].

Morbidity and complications from COVID-19 are more common in the elderly and immunocompromised patients, which highlights the importance of the immune response in staying off infection and minimizing the case fatality rate. The effect of opioids on the immune system is complex and depends on the type of opioid, dose, nature of immunity (i.e., opioids have different effects on different immune cells), and context [66]. In individuals on chronic opioid therapy, opioids have been linked to infection [67]. However, pain itself may have an immunosuppressive effect, such that the use of opioids to alleviate acute pain may actually enhance the immune response [68].

As noted above, the Department of Health and Human Services has provided a waiver permitting health care providers to prescribe opioids via telehealth visits, and most regions now permit electronic opioid prescriptions, which may reduce the risk of diversion. Considering these factors, it is reasonable to provide interim, short-term opioids, to individuals who experience an acute pain episode or severe exacerbation of chronic pain after appropriate risk stratification, screening for red flags, checking the prescription drug monitoring program, and developing an agreed-upon exit strategy. If opioids are to be continued in these individuals beyond one to two weeks, we recommend an in-person visit within one month if this is at all feasible to perform a physical examination in order to assess the severity of pathology and identify individuals who might be candidates for a procedural intervention or subspecialty referral, ensure symptom concordance, surveil nonorganic signs, obtain written informed consent, identify benchmarks for success, develop and discuss an exit strategy, and perform baseline urine toxicology screening as deemed appropriate [69,70]. When an in-person visit is not possible or impractical, electronic document-signing services can be utilized for informed consent. In individuals who are already taking opioids, temporary increases may be provided with the appropriate risk mitigation tools, but barring extenuating circumstances, we recommend that an in-person visit be performed ideally within two months. This may help distinguish disease progression that might warrant treatment from opioid tolerance, opioid hyperalgesia, and the use of opioids to treat nonpain conditions that might benefit from other treatments such as psychotherapy.

Intrathecal pump refills are an emergent interventional pain procedure. The most common intrathecally delivered medications include opioids, baclofen, bupivacaine, clonidine, and ziconotide. For opioids, clonidine and baclofen, withdrawal should be expected with abrupt cessation, which can be fatal for baclofen. The oral-to-intrathecal dose ratios vary from around 300:1 for opioids to ≥100:1 for baclofen, but even high-dose oral replacement therapy may not be sufficient for baclofen; there is extremely wide variability in conversion ratios, and conversion ratios have not been well studied for any drug besides morphine. For obese and anatomically challenging patients, imaging is sometimes used to ensure accurate medication deposit into the pump reservoir, which would require an in-person appointment. For most patients, in-home pump refills can be done by special services.

**Mental Health Considerations for Patients**

Key mental health problems associated with the COVID-19 pandemic include high rates of psychiatric symptoms, psychological stress associated with being quarantined, and the immediate need to deliver mental health screening and treatment interventions to large populations. These mental health considerations are highly relevant because mental health disorders (e.g., depression, anxiety disorders, post-traumatic stress disorder, and substance use disorders) are common in patients with chronic pain [71]. Mental health problems associated with the COVID-19 pandemic could exacerbate these preexisting conditions, which, in turn, could adversely impact pain-related treatment outcomes [72,73].

Three online survey studies (N = 3,586) from China, conducted from January 31 to February 8, 2020, provide important preliminary data about the impact of COVID-19 on the prevalence of psychiatric symptoms [74–76]. The psychological impact of the pandemic was rated as moderate-to-severe by 53.8% of respondents [76], 16.5–28.8% reported moderate-to-severe symptoms of depression and anxiety [76], 8.1% reported moderate-to-severe stress levels [76], and the prevalence of acute post-traumatic stress symptoms (PTSS) ranged from 4.6% to 7.0% [74,75]. Female gender, poor self-rated health status, and physical symptoms of myalgia, dizziness, and cough were significantly associated with greater levels of anxiety, depression, and stress [76]. Female gender, history of residing in Wuhan, high-risk viral exposure, and poor sleep quality were significantly associated with
greater levels of PTSS [74,75]. In addition to high levels of psychiatric symptoms, the widespread use of quarantines to halt the spread of COVID-19 is associated with significant psychological stress. Specific quarantine-related stressors include longer duration of confinement, fear of infection, frustration and boredom, inadequate home supplies and access to information, financial loss, and social stigma [77]. The effects of quarantine may be particularly deleterious for health care workers.

Mental Health Considerations for Health Care Workers

As summarized by Brooks et al. [77], quarantined health care workers are more likely to report exhaustion, social detachment, feelings of anxiety when treating febrile patients, irritability, sleep disruption, poor concentration and difficulty making decisions, poor work performance, and missed work days. Among health care workers, being quarantined is a significant predictor of alcohol abuse and symptoms of post-traumatic stress disorder for up to three years after the episode of quarantine [78,79]. In the context of the ongoing pandemic, widespread screening and treatment interventions for mental health problems should be immediately deployed [80]. A broad array of online and mobile-based platforms should be leveraged to accelerate dissemination of mental health services to the vast numbers of people impacted by the COVID-19 pandemic including health care workers [81,82]. These may include telehealth cognitive behavioral therapy, online stress reduction and coping skills training, and audio or audiovisual group therapy sessions (Box 1). Although mobile health technology has yielded auspicious results for the treatment of psychological distress, it may be less beneficial in the absence of a previously established therapeutic relationship.[83]

Steroids and Immunosuppression

Steroids are known to suppress the immune system, and systemic steroids have been linked to infections, including pneumonia [84]. Suppression of the hypothalamic–pituitary–adrenal axis typically lasts for less than three weeks but may last for over one month in some individuals [85,86]. Infections have also been reported after epidural and other steroid injections, though none have been causally linked to an immunosuppressed state in patients; most are linked to contaminated solutions or poor infection control practices [87]. However, an iatrogenically immunocompromised patient can be at increased risk for infection during the window of immune suppression, which occurs via the effects of glucocorticoids on the immune response, T cells, myeloid cells, and through alterations in gene expression [88]. According to one large retrospective study, influenza-vaccinated patients who underwent joint corticosteroid injections were 52% more likely to develop influenza than noninjection control patients, with women aged <65 years being at highest risk [89]. Yet, in a position paper from the Spine Intervention Society that did not include this study, the Patient Safety Committee concluded, “There is no clear evidence of a causative effect between spinal injections and periprocedural infections and complications in immunosuppressed patients” [87].

Many patients with chronic pain are on opioids, and the treatment of chronic pain with procedures may ameliorate the need for opioids, which are well documented to suppress the immune system [66,90]. In addition,
poorly treated pain may itself exert immunosuppressive effects [91]. Theoretically, the treatment of severe pain may therefore bolster one’s immune response.

However, there is at least a theoretical possibility that procedures involving the administration of steroids can increase infection risk, and corticosteroid administration should be approached with caution in these patients. Multiple randomized trials have evaluated different doses of epidural steroids, and for the most part they have found that the doses typically used in clinical practice and trials are excessive [72,92]. In recent guidelines from the World Institute of Pain, the authors found no evidence for interlaminar ESI doses exceeding 40 mg for methylprednisolone acetate, 20 mg for triamcinolone, and 10 mg for dexamethasone [92]. In two randomized studies evaluating multiple doses of steroids, the authors found no additional benefit for doses >10 mg of triamcinolone [93] or 4 mg of dexamethasone [94]. There is less literature on steroid dosing for intra-articular injections, though one randomized trial found no difference in outcomes between 40 mg and 80 mg of triamcinolone for knee injections [95].

Other literature supports the effects of non-steroid-based solutions for inflammatory conditions. A large systematic review by Bicket et al. [96] that compared the effectiveness of epidural nonsteroid and nonpudipar steroid “control” injections in ESI studies found that most of the short-term effect for epidural injections results from the injectate itself, rather than the steroids. The analgesic effects of nonsteroid injections were further illustrated in a systematic review by Rabinovitch et al. [97], who reported a strong correlation between epidural volume and pain relief irrespective of steroid dose for up to one year. For nonpudipar joint injections, randomized studies also suggest that nonsteroid injections, including saline, may provide significant benefit [98]. It is important to note that for many procedures such as trigger point injections, steroids concur no additional benefit beyond that achieved with nonsteroid solutions [99].

In summary, we believe that physicians may continue to perform epidural and other steroid injections as clinical conditions indicate during the COVID-19 pandemic. The lowest dose possible should be used, and patients should be informed of the possibility of immunosuppression and potential risk for infection. In patients who are already immunosuppressed and at high risk for SARS-CoV-2 infection and complications, epidural nonsteroid injections may be considered for radicular pain, though the possibility of treatment failure requiring a subsequent procedure must be weighed against the theoretical risk of infection.

Nonsteroidal anti-Inflammatory Drugs

Non-peer-reviewed case reports of several young patients infected with SARS CoV-2 deteriorating after taking ibuprofen generated concerns from health care providers and patients about the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) during the COVID-19 pandemic [100]. On March 18, 2020, the World Health Organization advised patients experiencing COVID-19 symptoms to avoid the use of ibuprofen, a position reversed by the organization the following day. The theory postulated for this was that NSAIDs could increase levels of angiotensin-converting enzyme-2 (ACE-2), which could increase susceptibility to infection or aggravate symptoms. Currently, neither the FDA nor the European Medicines Agency is aware of any evidence linking the use of ibuprofen or other NSAIDs to worsening COVID-19 symptoms [101,102], though the agencies do caution that “the pharmacological activity of NSAIDs in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.” Some of the common symptoms associated with COVID-19, including myalgia, headache, and fever, may be alleviated by NSAIDs. Acetaminophen is an alternative to NSAIDs, but has been shown in clinical trials to have less antipyretic and analgesic effects [103,104].

Conclusions

The COVID-19 pandemic represents an unprecedented global health crisis that requires carefully weighing the dynamic balance between access to pain care, which can have long-term personal and socioeconomic benefits, and the immediate goal of minimizing exposure risk for frontline health care providers and vulnerable patients. It is important to recognize that these recommendations are meant to serve as guidelines, not standards, which come from an undisputed, unquestioned authority and are therefore less subject to interpretation and modification. The risk–benefit calculation of performing in-person visits and procedures must take into account not only individual factors (e.g., psychological health, the likelihood of a patient to seek emergency services) and the probability of benefit, but also context, logistical concerns, relevant regulations and conditions in the area, and the availability of resources, all of which are constantly evolving. For patients for whom triage determines an in-person visit, general and pain-specific risk mitigation strategies should be adhered to.

Resources

- American Medical Association:
  - Provides guidance on COVID-19 for physicians.
  - https://www.ama-assn.org/delivering-care/public-health/covid-19-2019-novel-coronavirus-resource-center-physicians
- American Society of Anesthesiologists:
  - Provides anesthesiologists information on managing COVID-19 patients.
  - https://www.asahq.org/in-the-spotlight/coronavirus-covid-19-information
- American Society of Regional Anesthesia and Pain Medicine:
  - Provides updates on COVID-19 for regional anesthesia and pain medicine specialists.
• https://www.asra.com/page/2900/updates-on-covid-19-for-regional-anesthesia-and-pain-medicine-specialists
• Centers for Disease Control and Prevention:
  • Provides general information to the public about COVID-19.
  • https://www.cdc.gov/coronavirus/2019-ncov/index.html
• Centers for Disease Control and Prevention, Information for Healthcare Professionals:
  • Provides health care professionals information about caring for COVID-19 patients including resources for infection control and optimizing the use of personal protective equipment.
  • https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html
• Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report:
  • Provides scientific public health information and recommendations.
  • https://www.cdc.gov/mmwr/Novel_Coronavirus_Reports.html?deliveryName=USCDC_921-DM23064
• Centers for Disease Control and Prevention, Get Your Clinic Ready for Coronavirus Disease 2019 (COVID-19):
  • Provides information for health care providers on how to prepare clinics during the COVID-19 pandemic and how to communicate with patients.
  • https://www.cdc.gov/coronavirus/2019-ncov/downloads/Clinic.pdf
• Johns Hopkins University &Medicine Coronavirus Resource Center:
  • Provides up-to-date geographic information about active COVID-19 cases and deaths. Also gives expert advice and information about the virus and disease prevention.
  • https://coronavirus.jhu.edu
• The Lancet COVID-19 Resource Centre:
  • Provides health care workers and researchers information on COVID-19.
  • https://www.thelancet.com/coronavirus
• The New England Journal of Medicine:
  • Provides a collection of resources on COVID-19, including reports, management guidelines, and commentary.
  • https://www.nejm.org/coronavirus
• Spine Intervention Society:
  • Provides guidance on interventional pain procedures during the COVID-19 pandemic.
  • https://www.spineintervention.org/page/COVID-19
• US Department of Health and Human Services:
  • Provides key government updates as the lead federal agency for the COVID-19 response.
  • https://www.hhs.gov/about/news/coronavirus/index.html
• World Health Organization:
  • Provides COVID-19 guidance on a per-country basis.
  • https://www.who.int/emergencies/diseases/novel-coronavirus-2019
• Lahey Clinic Instructional Videos:
  • Provides visual instruction on donning and doffing personal protective gear.
  • https://www.youtube.com/watch?v=KQtesKKZY4
  • https://www.youtube.com/watch?v=ELZBr0I7C78

Acknowledgments
The authors would like to thank Ashley Walton for her inspirational and administrative support for this endeavor.

Supplementary Data
Supplementary data are available at Pain Medicine online.

References
1. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: Burden of diseases, injuries, and risk factors. JAMA 2013;310(6):591–608.
2. St Sauver JL, Warner DO, Yawn BP, et al. Why patients visit their doctors: Assessing the most prevalent conditions in a defined American population. Mayo Clin Proc 2013;88(1):56–67.
3. Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1859–922.
4. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13(8):715–24.
5. Smith D, Wilkie R, Uthman O, Jordan JL, McBeth J. Chronic pain and mortality: A systematic review. PLoS One 2014;9(6):e99048.
6. Tang NK, Crane C. Suicide risk in chronic pain: A review of the prevalence, risk factors and psychological links. Psychol Med 2006;36(05):575–86.
7. Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 2015;16(6):769–80.
8. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. BMJ Open 2016;6(6):e010364.
9. Brennan F, Carr D, Cousins M. Access to pain management: still very much a human right. Pain Med 2016;17(10):1785–9.
10. Jukic M, Puljak L. Legal and ethical aspects of pain management. Acta Med Acad 2018;47:18–26.
11. National Center for Health Statistics. Health, United States, 2010. With Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics; 2011.
12. Cauda F, Palermo S, Costa T, et al. Gray matter alterations in chronic pain: A network-oriented meta-analytic approach. Neuroimage Clin 2014;4:676–86.
13. Cohen SP, Hooten WM. Balancing the risks and benefits of opioid therapy: The pill and the pendulum. Mayo Clin Proc 2019;94(12):2385–9.
14. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10(9):865–71.
15. Cohen SP, Gallagher RM, Davis SA, Griffith SR, Carragee EJ. Spine-area pain in military personnel: A review of epidemiology, etiology, diagnosis, and treatment. Spine J 2012;12(9):833–42.
16. Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci U S A 2016;113(16):4296–301.
17. Racine M. Chronic pain and suicide risk: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2018;87:269–80.
18. White RL, Cohen SP. Return-to-duty rates among coalition forces treated in a forward-deployed pain treatment center: A prospective observational study. Anesthesiology 2007;107(6):1003–8.
19. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924.

20. Santarpia JL, Rivera DN, Herrera V, et al. Transmission potential of SARS-CoV-2 in viral shedding observed at the University of Nebraska Medical Center. Preprint. Posted online March 26, 2020. medRxiv 2020.03.23.20039446. doi:10.1101/2020.03.23.20039446.

21. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382(12):1177–9.

22. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323(15):1488–94.

23. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 59. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdf9_2 (accessed June 2020).

24. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69(12):343–6.

25. Centers for Disease Control and Prevention. Are you at higher risk for severe illness? Available at: https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/high-risk-complications.html. Last reviewed March 20, 2020. Accessed April 3, 2020.

26. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020;18:18.

27. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323(16):1612–4.

28. Centers for Disease Control and Prevention. Strategies for optimizing the supply of N95 respirators: Crisis/alternate strategies. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirators-strategy/crisis-alternate-strategies.html. Accessed April 2, 2020.

29. National Institute for Occupational Safety and Health. Respirator trusted-source information page. 2018. Available at: https://www.cdc.gov/niosh/nptt/topics/respirators/disp_part/RespSource.html. Accessed April 3, 2020.

30. Centers for Disease Control and Prevention. Questions and answers regarding respiratory protection for preventing 2009 H1N1 influenza among healthcare personnel. Available at: https://www.cdc.gov/h1n1flu/guidelines_infection_control_qa.htm. Accessed April 3, 2020.

31. Institute of Medicine. Reusability of Face masks during an Influenza Pandemic: Facing the Flu. Washington, DC: National Academies Press; 2006.

32. Hines L, Rees E, Pavelchak N. Respiratory protection policies and practices among the health care workforce exposed to influenza in New York State: Evaluating emergency preparedness for the next pandemic. Am J Infect Control 2014;42(3):240–5.

33. Casanova L, Rutala WA, Weber DJ, Sobsey MD. Coronavirus survival on healthcare personal protective equipment. Infect Control Hosp Epidemiol 2010;31(5):560–1.

34. Centers for Disease Control and Prevention. Pandemics: Recommended guidance for extended use and limited reuse of N95 filtering facepiece respirators in healthcare settings. Available at: https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html. Accessed April 3, 2020.

35. American Society of Anesthesiologists. Update: The use of personal protective equipment by anesthesia professionals during the COVID-19 pandemic. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2020/03/update-the-use-of-personal-protective-equipment-by-anesthesia-professionals-during-the-covid-19-pandemic. Accessed April 3, 2020.

36. Centers for Disease Control. Hospital pandemic influenza planning checklist. https://www.cdc.gov/flu/pandemic-resources/pdf/hospitalchecklist.pdf. Accessed April 3, 2020.

37. Jernigan B, CDC COVID-19 Response Team. Update: Public health response to the coronavirus disease 2019 outbreak - United States, February 24, 2020. MMWR Morb Mortal Wkly Rep 2020;69(8):216–9.

38. US Department of Health and Human Services. Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency. Available at: https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html. Accessed April 2, 2020.

39. Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet. Available at: https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet. Published March 17, 2020. Accessed April 2, 2020.

40. Federation of State Medical Boards. Telemedicine policies. Available at: https://www.fsmb.org/siteassets/advocacy/key-issues/telemedicine_policies_by_state.pdf. Last updated November 2019. Accessed April 3, 2020.

41. Sundararaman LV, Edwards RR, Ross EL, Jamison RN. Integration of mobile health technology in the treatment of chronic pain: A critical review. Reg Anesth Pain Med 2017;42(4):488–98.

42. Mathersul DC, Mahoney LA, Bayley PJ. Tele-yoga for chronic pain: Current status and future directions. Glob Adv Health Med 2018;7:2164956118766011.

43. Schauer AGM, Zalpour C, von Piekartz H, Hall TM, Paelke V. The efficacy of electronic health-supported home exercise interventions for patients with osteoarthritis of the knee: Systematic review. J Med Internet Res 2018;20(4):e152.

44. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. Available at: https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html. CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2FCoronavirus%2F2019-ncov%2Fncov%2FHCIN infectious-control-discretion.html. Accessed April 3, 2020.

45. Centers for Disease Control and Prevention. Get your clinic ready for coronavirus disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/downloads/clinic.pdf. Accessed April 3, 2020.

46. Bazyar J, Farrokhi M, Khankeh H. Triage systems in mass casualty incidents and disasters: A review study with a worldwide approach. Open Access Maced J Med Sci 2019;7(3):482-94.

47. Frykberg ER. Medical management of disasters and mass casualties from terrorist bombings: How can we cope? J Trauma 2002;53(2):201–12.

48. Koenig KL, Cone DC, Burstein JL, Camargo CA Jr. Surging to the right standard of care. Acad Emerg Med 2006;13(2):195–8.

49. Altevogt BM, Stroud C, Hanson SL, Hanfling D, Gostin LO, eds. Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations: A Letter Report. Institute of Medicine (US), Committee on Guidance for Establishing Standards of Care for Use in Disaster Situations. Washington, DC: National Academies Press, US; 2009.

50. Altevogt BM, Stroud C, Hanson SL, Hanfling D, Gostin LO, eds. Guidance for Establishing Crisis Standards of Care for Use
Pain Management Best Practices from Multispecialty Organizations During the COVID-19 Pandemic

67. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of suicide in patients with lumbar spinal stenosis. Spine (Phila Pa 1976) 2016;41(16):E1053–62.

68. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14(2):162–73.

69. Thornton JD, Goyat R, Dwibedi N, Kelley GA. Stress-related quality of life in patients receiving long-term opioid therapy: A systematic review with meta-analysis. Qual Life Res 2017;26(8):1955–67.

70. Hyman SM, Fox H, Hong KI, Doebrick C, Sinha R. Stress and pain-cue-induced craving in opioid-dependent individuals in naloxone treatment. Exp Clin Psychopharmacol 2007;15(2):134–43.

71. Johnson AC, Greenwood-Van Meerveld B. Stress-induced pain: A target for the development of novel therapeutics. J Pharmacol Exp Ther 2014;351(2):327–35.

72. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 2008;1141(1):105–30.

73. Ahmad J, Jahromi MS. Anxiety treatment of opioid dependent patients with buprenorphine: A randomized, double-blind, clinical trial. Indian J Psychol Med 2017;39(4):445–9.

74. Yovel Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: A randomized controlled trial. Am J Psychiatry 2016;173(5):491–8.

75. Artech J, Cobos B, Hu Y, Jordan K, Howard K. Evaluation of how depression and anxiety mediate the relationship between pain catastrophizing and prescription opioid misuse in a chronic pain population. Pain Med 2015;17:295–303.

76. Rosen IM, Aurora RN, Kirsch DB, et al. Chronic opioid therapy and sleep: An American Academy of Sleep Medicine position statement. J Clin Sleep Med 2019;15(11):1671–3.

77. Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain 2018;34(9):878–84.

78. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol 2018;175(14):2717–25.

79. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: A population-based case-control study. J Am Geriatr Soc 2011;59(10):1899–907.

80. Page GG. Immunologic effects of opioids in the presence of absence of pain. J Pain Symptom Manage 2005;29(5):23–31.

81. Cohen SP, Raja SN. The middle way: A practical approach to prescribing opioids for chronic pain. Nat Clin Pract Neurol 2006;2(11):580–1.

82. Ho CS, Chee CY, Ho RC. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singapore 2020;49(6):706–12.

83. Wu P, Yang Y, Guan Z, et al. The psychological impact of the SARS epidemic on hospital employees in China: Exposure, risk perception, and altruistic acceptance of risk. Can J Psychiatry 2009;54(3):302–11.

84. Wu P, Liu X, Fang Y, et al. Alcohol abuse/dependence symptoms among hospital employees exposed to a SARS outbreak. Alcohol Alcohol 2008;43(6):706–12.

85. Abdul AJ, Ghai B, Bansal D, et al. Hypothalamic pituitary adrenocortical axis suppression following a single epidural injection of methylprednisolone acetate. Pain Physician 2017;20(4):300–2.

86. Ho CS, Chee CY, Ho RC. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singapore 2020;49(3):153–60.

87. Donelan K, Barreto EA, Sosson S, et al. Patient and clinician experience with telehealth for patient follow-up care. Am J Med 2019;25:40–4.

88. Almirall J, Serra-Prat M, Boliar B, Balasso V. Risk factors for community-acquired pneumonia in adults: A systematic review of observational studies. Respiration 2017;94(3):299–311.

89. Abdul AJ, Ghai B, Bansal D, et al. Hypothalamic pituitary adrenocortical axis suppression following a single epidural injection of methylprednisolone acetate. Pain Physician 2017;20(4):300–2.
and mechanistic insights. Mol Cell Endocrinol 2011;335(1):2–13.
89. Sytsma TT, Greenlund LK, Greenlund LS. Joint corticosteroid injection associated with increased influenza risk. Mayo Clin Proc Innov Qual Outcomes 2018;2(2):194–8.
90. Pollard EM, Lamer TJ, Moeschler SM, et al. The effect of spinal cord stimulation on pain medication reduction in intractable spine and limb pain: A systematic review of randomized controlled trials and meta-analysis. J Pain Res 2019;12:1311–24.
91. Page GG. The immune-suppressive effects of pain. Madame Curie Bioscience Database. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6140/. Accessed March 31, 2020.
92. Van Boxem K, Rijsdijk M, Hans G, et al. Safe use of epidural corticosteroid injections: Recommendations of the WIP Benelux Work Group. Pain Pract 2019;19(1):61–92.
93. Kang SS, Hwang BM, Son HJ, et al. The dosages of corticosteroid in transforaminal epidural steroid injections for lumbar radicular pain due to a herniated disc. Pain Physician 2011;14(4):361–70.
94. Ahadian FM, McGreevy K, Schulteis G. Lumbar transforaminal epidural dexamethasone: A prospective, randomized, double-blind, dose-response trial. Reg Anesth Pain Med 2011;36(6):572–8.
95. Popma JW, Snel FW, Haagsma CJ, et al. Comparison of 2 dosages of intraarticular triamcinolone for the treatment of knee arthritis: Results of a 12-week randomized controlled clinical trial. J Rheumatol 2015;42(10):1865–8.
96. Bicket MC, Gupta A, Brown CH, Cohen SP. Epidural injections for spinal pain: A systematic review and meta-analysis evaluating the “control” injections in randomized controlled trials. Anesthesiology 2013;119(4):907–31.
97. Rabinovitch DL, Peliwoski A, Furlan AD. Influence of lumbar epidural injection volume on pain relief for radicular leg pain and/or low back pain. Spine J 2009;9(6):509–17.
98. Egsmose C, Lund B, Bach Andersen R. Hip joint distension in osteoarthritis. A triple-blind controlled study comparing the effect of intra-articular indoprofen with placebo. Scand J Rheumatol 1984;13(3):238–42.
99. Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: A systematic review. Arch Phys Med Rehabil 2001;82(7):986–92.
100. Day M. COVID-19: European drugs agency to review safety of ibuprofen. BMJ 2020;368:m1168.
101. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020. Available at: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. Accessed March 22, 2020.
102. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. Accessed March 22, 2020.
103. Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: A systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2017;166(7):480–92.
104. Kauffman RE, Sawyer LA, Scheinbaum ML. Antipyretic efficacy of ibuprofen vs acetaminophen. Am J Dis Child 1992;146(5):622–5.